Abstract
Human immunodeficiency virus (HIV)-1 Nef is a regulatory protein critically involved in AIDS pathogenesis. We previously demonstrated that extracellular Nef is efficiently internalized by human primary monocyte-derived macrophages (MDMs), thereby activating a number of transcription factors including STATs, MAPKs, IRF-3, and NF-κB. Such an activation state leads to the release of inflammatory factors whose paracrine effects deserve deep consideration. Here, we demonstrate that quiescent CD4 lymphocytes undergo cell activation when cultivated in supernatants from autologous MDMs treated with extracellular wt Nef but not with its counterpart mutated in the 72PxxP75 polyproline domain. Of a pathogenetic relevance, this effect coupled with the sensitization of quiescent CD4 lymphocytes to HIV-1 infection. By microarray assay, we found that the CCL24/eotaxin-2 gene was up-regulated in MDMs treated with wt Nef but not with the 72AxxA75 mutant. In addition, the higher transcription activity correlated with a significant increase of the CCL24/Eotaxin-2 release. Finally, we observed that anti-CCL24/eotaxin-2 antibodies efficiently neutralized the stimulatory effect on CD4 lymphocytes of supernatants from MDMs treated with extracellular Nef. Overall, these data support the idea that CCL24/eotaxin-2 is part of the mechanism of CD4 lymphocyte activation paracrinally induced by Nef.
Keywords: Macrophages, HIV-1, nef, microarray, CCL24/eotaxin-2
Current Drug Discovery Technologies
Title: Microarray Analysis Reveals CCL24/Eotaxin-2 as an Effector of the Pathogenetic Effects Induced by HIV-1 Nef
Volume: 4 Issue: 1
Author(s): Gianna Fiorucci, Eleonora Olivetta, Maria Vincenza Chiantore and Maurizio Federico
Affiliation:
Keywords: Macrophages, HIV-1, nef, microarray, CCL24/eotaxin-2
Abstract: Human immunodeficiency virus (HIV)-1 Nef is a regulatory protein critically involved in AIDS pathogenesis. We previously demonstrated that extracellular Nef is efficiently internalized by human primary monocyte-derived macrophages (MDMs), thereby activating a number of transcription factors including STATs, MAPKs, IRF-3, and NF-κB. Such an activation state leads to the release of inflammatory factors whose paracrine effects deserve deep consideration. Here, we demonstrate that quiescent CD4 lymphocytes undergo cell activation when cultivated in supernatants from autologous MDMs treated with extracellular wt Nef but not with its counterpart mutated in the 72PxxP75 polyproline domain. Of a pathogenetic relevance, this effect coupled with the sensitization of quiescent CD4 lymphocytes to HIV-1 infection. By microarray assay, we found that the CCL24/eotaxin-2 gene was up-regulated in MDMs treated with wt Nef but not with the 72AxxA75 mutant. In addition, the higher transcription activity correlated with a significant increase of the CCL24/Eotaxin-2 release. Finally, we observed that anti-CCL24/eotaxin-2 antibodies efficiently neutralized the stimulatory effect on CD4 lymphocytes of supernatants from MDMs treated with extracellular Nef. Overall, these data support the idea that CCL24/eotaxin-2 is part of the mechanism of CD4 lymphocyte activation paracrinally induced by Nef.
Export Options
About this article
Cite this article as:
Gianna Fiorucci , Eleonora Olivetta , Maria Vincenza Chiantore and Maurizio Federico , Microarray Analysis Reveals CCL24/Eotaxin-2 as an Effector of the Pathogenetic Effects Induced by HIV-1 Nef, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115502
DOI https://dx.doi.org/10.2174/157016307781115502 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of <i>In Vitro</i> and <i>In Vivo</i> Effects of Infliximab on Cytokine Production in Proliferating CD4+ T Cells in Patients with Rheumatoid Arthritis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Carbon Monoxide and the Pancreas
Current Pharmaceutical Biotechnology Structure-Activity Relationships of p38 Mitogen-Activated Protein Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Species-Specific and Age-Dependent Bile Acid Composition: Aspects on CYP8B and CYP4A Subfamilies in Bile Acid Biosynthesis
Current Drug Metabolism Myc - What We have Learned from Flies
Current Drug Targets Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets Inhibition of HIV-1 Replication by RNA-Based Strategies
Current HIV Research Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational Gastroenterology Comes of Age)
Current Drug Targets Editorial [Hot Topic: Tumor Necrosis Factor (Guest Editor: Francis Ka-Ming Chan)]
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Antiviral Effects of Asian Natural Products Targeting SARS, MERS, and COVID-19
Coronaviruses Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Opioid-induced Nausea and Vomiting: Mechanisms and Strategies for their Limitation
Current Pharmaceutical Design Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Old Versus New Anticoagulants: Focus on Pharmacology
Recent Patents on Cardiovascular Drug Discovery Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Dual Role of Interleukin-25 in the Control of Immune-Mediated Pathologies
Current Molecular Medicine